Mumbai-based e-pharmacy and telehealth platform Truemeds has raised $85 million in its Series C funding round led by Accel and Peak XV Partners, with participation from WestBridge Capital and Info Edge Ventures. The round was completed in two tranches. The company plans to use the capital to expand its presence in non-metro regions by opening new fulfillment centers, strengthening its engineering and product teams, and setting up a new office in Bengaluru. Truemeds also intends to triple its national penetration and enter diagnostic services in the coming months. Founded in 2019 by Akshat Nayyar and Dr. Kunal Wani, the platform offers clinically equivalent alternatives to branded medicines, helping patients save 50–70% on monthly costs. It primarily caters to chronic care patients, including those managing diabetes, hypertension, and cardiovascular conditions.
Truemeds currently employs about 3,000 people, including a 250-member head office team, and works with around 600 doctors daily. Commenting on the funding, Nayyar said, “Our vision is simple—to bring the lowest prices for medicines in India, while ensuring every patient gets the quality they can trust.” Accel Partner Abhinav Chaturvedi highlighted the platform’s role in addressing affordability, saying, “Truemeds is bridging this gap with a clinically guided, technology-led platform that delivers transparency and accessibility at scale.” Peak XV Partners’ Sakshi Chopra added, “Their mission to make chronic care affordable for millions, especially in underserved non-metro markets, is both timely and transformative.” With this funding, Truemeds is positioned to expand its role in India’s healthcare market by focusing on affordability, accessibility, and innovation in chronic care.
